Please login to the form below

Not currently logged in
Email:
Password:

COPD asthma

This page shows the latest COPD asthma news and features for those working in and with pharma, biotech and healthcare.

Boehringer Ingelheim and VisionHealth collaborate on distribution of digital Kata platform

Boehringer Ingelheim and VisionHealth collaborate on distribution of digital Kata platform

Boehringer Ingelheim is set to work in cooperation with VisionHealth on the Kata app to provide therapy support for those living with asthma and chronic obstructive pulmonary disease (COPD). ... VisionHealth created the Kata app with the goal of guiding

Latest news

More from news
Approximately 7 fully matching, plus 86 partially matching documents found.

Latest Intelligence

  • AI: the smart money is on the smart thinking AI: the smart money is on the smart thinking

    The software helps differentiate patients from those suffering with similar symptoms that are actually a result of asthma and chronic obstructive pulmonary disease (COPD), and therefore diagnose CTEPH more reliably and

  • A snapshot of… Enterprise Therapeutics A snapshot of… Enterprise Therapeutics

    of infection in respiratory diseases such as cystic fibrosis (CF) and COPD. ... In addition, we have the opportunity to evaluate the clinical efficacy of our drugs in other muco-obstructive lung diseases such as COPD, severe asthma, bronchiectasis and

  • GSK forges ahead with its dynamic COPD and asthma portfolio GSK forges ahead with its dynamic COPD and asthma portfolio

    The emergence of eosinophil counts as a biomarker in COPD has been helpful. ... You would imagine coronavirus would be one of those threats.”. GSK is trialling its biologic anti IL-5 drug mepolizumab, licensed for severe asthma, in eosinophilic COPD

  • AstraZeneca: building a new ‘open innovation’ pharma company AstraZeneca: building a new ‘open innovation’ pharma company

    AstraZeneca launched five significant new medicines in 2017: immunotherapy Iminzi, Calquence for mantle cell lymphoma, Qtern in type 2 diabetes, Bevespi Aerosphere in COPD and Fasenra for severe asthma.

  • The good, the bad and the ugly The good, the bad and the ugly

    Its revenues grew by a further 9% last year. “A large percentage of this growth was driven by Ellipta, but Nucala - a biologic approved for asthma and COPD - also played its ... The category has also seen the recent introduction of a major drug class

More from intelligence
Approximately 0 fully matching, plus 14 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Mednet Group

PMEA Agency of the year 2021. With diversity and inclusion at our core, Mednet Group consists of Attigo CIC and...

Latest intelligence

Animation: Living With
The journey from the patient's perspective...
Danny Buckland July2022
Achieving communication excellence by targeting the right channel at the right time
By Danny Buckland...
6 trends shaping the future of personalized medicine
Senior Consultant Leah Carlisle explores the key trends discussed at the 16th annual Personalized Medicine Conference, providing expert analysis and key recommendations for biopharmaceutical innovators....